A new study of the scientific literature finds that researchers are guilty of overemphasizing the benefits of medical treatments.
Advertisement
The Scientist
Most Recent
Doctors question whether a government initiative to speed approval for promising new drugs is ensuring safety.
The US Food and Drug Administration will consider whether or not to stop the use of intravenous starch solutions to replace lost blood.
Results from a Phase II trial for cardiovascular disease with an epigenetic target therapy show promise.
A human trial of a hepatitis C treatment is shut down after one of the participants died.
A former manager at Genentech claims the company bypassed ethical and clinical guidelines in order to rush a promising drug through clinical trials.
A slight flaw in a study on the effectiveness of a drug widely used to combat shock in critically injured patients almost gets a Danish researcher sued for millions.
To cope with a growing shortage of hearts, livers, and lungs suitable for transplant, some scientists are genetically engineering pigs, while others are growing organs in the lab.
After years of complaints, the European Commission proposes ways to fix its system in an effort to reinvigorate research on the continent.
A trial comparing the effectiveness of robotic surgery and radiation for the treatment of throat cancer has begun in Canada.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
